Health-Care Stocks: The Obama Effect
S&P fairness analysts examine the ramifications for the habitual devotion to labor of potential policy moves by the new Administration
By Herman Saftlas, Steven Silver, Phillip Seligman, Jeffrey Loo, CFA and Jeffrey Englander, CFA From Standard & Poor’s Equity Research
While we believe greater degree of pressing general economic issues will take precedence, we still think health-care reform will have being a key priority in the Obama Administration. With Democrats now in sway of both the White House and Congress, we believe they now have the opportunity to pass meaningful reform legislation to provide health-care insurance coverage for some 46 million uninsured Americans (15% of the total population).
The new coverage, funded to a large extent by the federal command (which most experts estimate will cost betwixt $120 billion and $150 billion, depending upon the scope of the bale), would likely expand access to health care and increase revenues beneficial to providers of medical products and services, including pharmaceutical companies.
However, the Obama program likewise calls for significant cost reductions, that we be persuaded would adversely affect the branded pharmaceutical labor in terms of both discounted pricing and contracted use of branded drugs.
Change in Medicare Part D ComingThe explanation issue, in our opinion, is the planned elimination of the noninterference provision in the Medicare Part D direction drug program, which funds drug coverage for some 44 million somewhat old Americans. Under the present system, the government is prohibited from engaging in Medicare drug pricing negotiations with pharmaceutical manufacturers. Negotiations are handled strictly through private-sector managed care and pharmacy benefit management firms.
President-Elect Obama and congressional Democrats favor changing the program to allow or possibly require direct government negotiations with drug manufacturers, which is expected to sharply lower the program’s require to be paid. Another likely money-saving tactic will be greater use of inexpensive generics through unaccustomed incentives.
We have "substantial buy" recommendations on Abbott Laboratories (ABT) and Johnson & Johnson (JNJ). We think these companies are well-positioned in growing pharmaceutical, device, and consumer health-care markets. In the domestic pure play pharma segment, we have buys without interruption Bristol-Myers (BMY) and Schering-Plough (SGP). Our recommendations in the generic room are Teva Pharmaceutical Industries (TEVA) and Watson Pharmaceuticals (WPI).
BIOTECHWe have a generally contributing outlook for the biotech sector under the Obama presidency. We see increased funding in opposition to the Food & Drug Administration and National Institutes of Health, which should help the FDA stay current steady science-related investigation and approve starting anew drugs on schedule, and allow the NIH to conduct clinical studies and prefer innovative research end new grants. In adding, we expect an Obama Administration to supporter the progress of embryonic stem-cell exploration, which may open new avenues to treat serious diseases.
On the negative side, we think Obama will be a staunch supporter of implementing a new regulatory pathway in favor of generic drugs. Competition from generic biotech drugs would put pressure on drug pricing, and look sullen returns that we confident are that cannot be spared for firms to recoup investments and to support pharmaceutical and biotechnology innovation.
We have strong buy recommendations on Genzyme (GENZ) and Celgene (CELG).
Original text: {news-link}
